Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Eskandary, Farsad ^a   Bond, Gregor ^a   Schwaiger, Elisabeth ^a   Kikic, Zeljko ^a   Winzer, Christine ^a   Wahrmann, Markus ^a   Marinova, Lena ^a   Haslacher, Helmuth ^a   Regele, Heinz ^a   Oberbauer, Rainer ^a,b   Böhmig, Georg A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ELISABETHINEN HOSPITAL   (Austria)

Author keywords

Antibody mediated rejection; Bortezomib; Donor specific antibody; Kidney transplantation; Proteasome inhibition

Indexed keywords

ANTIBODY; ANTIVIRUS AGENT; BORTEZOMIB; CYCLOSPORIN A; DONOR SPECIFIC ANTIBODY; EVEROLIMUS; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; VALACICLOVIR; ALLOANTIBODY; BIOLOGICAL MARKER; BORONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG DOSE INCREASE; DRUG SAFETY; ELECTRON MICROSCOPY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; GOOD CLINICAL PRACTICE; GOOD LABORATORY PRACTICE; GRAFT RECIPIENT; HERPES ZOSTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LATE ANTIBODY MEDIATED KIDNEY TRANSPLANT REJECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OUTPATIENT CARE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; VIRUS INFECTION; AUSTRIA; BIOPSY; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; HUMORAL IMMUNITY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY TRANSPLANTATION; METHODOLOGY; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; AUSTRIA; BIOLOGICAL MARKERS; BIOPSY; BORONIC ACIDS; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; PROTEASOME INHIBITORS; PYRAZINES; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899992018     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-107     Document Type: Article

References (40)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant 2004, 4:1289-1295. 10.1111/j.1600-6143.2004.00515.x, 15268730.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011, 11:450-462. 10.1111/j.1600-6143.2010.03283.x, 20973913.
3. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003, 3:665-673. 10.1034/j.1600-6143.2003.00135.x, 12780557.
4. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18:1046-1056. 10.1681/ASN.2007010073, 17360947.
5. Bartel G, Schwaiger E, Böhmig GA. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011, 24:1142-1155. 10.1111/j.1432-2277.2011.01309.x, 21831227.
6. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714. 10.1034/j.1600-6143.2003.00072.x, 12780562.
7. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Cendales L, Demetris AJ, Drachenberg CB, Farver CF, Rodriguez ER, Wallace WD, Glotz D, . Banff Meeting Report Writing Committee Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012, 12:563-570. 10.1111/j.1600-6143.2011.03926.x, 3728651, 22300494, Banff Meeting Report Writing Committee.
8. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, Williams WW, Cosimi AA, Schneeberger EE, Colvin RB. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001, 12:574-582.
9. Regele H, Böhmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S, Watschinger B, Kerjaschki D, Exner M. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002, 13:2371-2380. 10.1097/01.ASN.0000025780.03790.0F, 12191982.
10. Racusen LC, Regele H. The pathology of chronic allograft dysfunction. Kidney Int Suppl 2010, 119:S27-S32.
11. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002, 74:1192-1194. 10.1097/00007890-200210270-00025, 12438971.
12. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009, 9:2520-2531. 10.1111/j.1600-6143.2009.02799.x, 19843030.
13. Lachmann N, Terasaki PI, Budde K, Liefeldt L, Kahl A, Reinke P, Pratschke J, Rudolph B, Schmidt D, Salama A, Schönemann C. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009, 87:1505-1513. 10.1097/TP.0b013e3181a44206, 19461487.
14. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010, 90:68-74.
15. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2011, 12:388-399.
16. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000, 70:887-895. 10.1097/00007890-200009270-00006, 11014642.
17. Böhmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, Soliman T, Bauer P, Mullner M, Druml W. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007, 7:117-121. 10.1111/j.1600-6143.2006.01613.x, 17109725.
18. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011, 11:2405-2413. 10.1111/j.1600-6143.2011.03757.x, 21942930.
19. Akalin E, Sehgal V, Murphy B, Akalin E, Sehgal V, Ames S, Bromberg JS, Murphy B, Dikman S, Fotino M. Intravenous immunoglobulin treatment in a kidney transplant patient with chronic allograft nephropathy. Transplantation 2005, 79:257-258. 10.1097/01.TP.0000144331.18842.34, 15665787.
20. Billing H, Rieger S, Ovens J, Susal C, Melk A, Waldherr R, Opelz G, Tonshoff B. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008, 86:1214-1221. 10.1097/TP.0b013e3181880b35, 19005402.
21. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 1837-1841, 2009:87.
22. Billing H, Rieger S, Susal C, Waldherr R, Opelz G, Wuhl E, Tonshoff B. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 2012, 25:1165-1173. 10.1111/j.1432-2277.2012.01544.x, 22897111.
23. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009, 9:1099-1107. 10.1111/j.1600-6143.2009.02591.x, 19422335.
24. Perry DK, Pollinger HS, Burns JM, Rea D, Ramos E, Platt JL, Gloor JM, Stegall MD. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008, 8:133-143.
25. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755. 10.1038/nm1763, 18542049.
26. Cascio P, Oliva L, Cerruti F, Mariani E, Pasqualetto E, Cenci S, Sitia R. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008, 38:658-667. 10.1002/eji.200737743, 18253932.
27. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
28. Everly JJ, Walsh RC, Alloway RR, Woodle ES. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009, 14:662-666. 10.1097/MOT.0b013e328330f304, 19667989.
29. Everly MJ. A summary of bortezomib use in transplantation across 29 centers. Clin Transpl 2009, 323-337.
30. Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 2012, 81:1067-1074. 10.1038/ki.2011.502, 22336990.
31. Vogelbacher R, Meister S, Guckel E, Starke C, Wittmann S, Stief A, Voll R, Daniel C, Hugo C. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 2011, 25:3764-3773.
32. Schwaiger E, Regele H, Wahrmann M, Werzowa J, Haidbauer B, Schmidt A, Böhmig GA. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report. Clin Transpl 2010, 391-396.
33. Lubetzky M, Auli MJ, Walker J, Leeser D, Kapur S, Hartono C, Dadhania D. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection. Clin Transpl 2010, 437-440.
34. Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, Sellares J, Reeve J, Halloran PF. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009, 9:2532-2541. 10.1111/j.1600-6143.2009.02800.x, 19843031.
35. Randomizer for Clinical Trials. [https://www.meduniwien.ac.at/randomizer].
36. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994, 13:1341-1352. discussion 1353-1356, 10.1002/sim.4780131308, 7973215.
37. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004, 141:929-937. 10.7326/0003-4819-141-12-200412210-00009, 15611490.
38. Gera M, Slezak JM, Rule AD, Larson TS, Stegall MD, Cosio FG. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. Am J Transplant 2007, 7:880-887. 10.1111/j.1600-6143.2006.01690.x, 17391131.
39. Tait BD, Hudson F, Cantwell L, Brewin G, Holdsworth R, Bennett G, Jose M. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009, 14:247-254. 10.1111/j.1440-1797.2008.01074.x, 19207861.
40. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002, 62:311-318. 10.1046/j.1523-1755.2002.00424.x, 12081593.